Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 10/20 | 0.53 |
| ▸ | HCRTR2 | O43614 | 10/20 | 0.53 |
| ▸ | CASP3 | P42574 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | MMP1 | P03956 | 2/20 | 0.41 |
| ▸ | MMP3 | P08254 | 2/20 | 0.41 |
| ▸ | MMP7 | P09237 | 2/20 | 0.41 |
| ▸ | MMP13 | P45452 | 2/20 | 0.41 |
| ▸ | MMP2 | P08253 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28305430 | 1.00 | HCRTR1 (0.53) | HCRTR1HCRTR2CASP3ALDH1A1MMP1 | |
| SCHEMBL19975403 | 0.97 | HCRTR1 (0.50) | HCRTR1HCRTR2CASP3ALDH1A1MMP1 | |
| SCHEMBL19975007 | 0.85 | HCRTR1 (0.52) | HCRTR1HCRTR2ALDH1A1MMP13SMN1; SMN2 | |
| SCHEMBL19975006 | 0.85 | HCRTR1 (0.52) | HCRTR1HCRTR2ALDH1A1MMP13SMN1; SMN2 | |
| SCHEMBL29360904 | 0.83 | HCRTR1 (0.51) | HCRTR1HCRTR2CASP3ALDH1A1FKBP1A | |
| SCHEMBL21291444 | 0.83 | HCRTR1 (0.51) | HCRTR1HCRTR2CASP3ALDH1A1FKBP1A | |
| SCHEMBL14265258 | 0.83 | CASP3 (0.49) | HCRTR1HCRTR2CASP3ALDH1A1MMP2 | |
| SCHEMBL19984568 | 0.82 | ALDH1A1 (0.49) | HCRTR1HCRTR2ALDH1A1MMP13FKBP1A | |
| SCHEMBL3115162 | 0.80 | HCRTR1 (0.62) | HCRTR1HCRTR2CASP3ALDH1A1MMP1 | |
| SCHEMBL3096773 | 0.80 | HCRTR1 (0.62) | HCRTR1HCRTR2CASP3ALDH1A1MMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220023311-A1 | HEPATITIS B CORE PROTEIN MODULATORS | ASSEMBLY BIOSCIENCES INC (US) | 2022-01-27 | — | — | US | disclosed |
| US-10987360-B2 | Hepatitis B core protein modulators | ASSEMBLY BIOSCIENCES, INC. (US) | 2021-04-27 | — | — | US | disclosed |
| US-20190255067-A1 | HEPATITIS B CORE PROTEIN MODULATORS | ASSEMBLY BIOSCIENCES INC (US) | 2019-08-22 | — | — | US | disclosed |
| WO-2018053157-A1 | HEPATITIS B CORE PROTEIN MODULATORS | ASSEMBLY BIOSCIENCES, INC. (US) | 2018-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10987360-B2 | Hepatitis B core protein modulators | HAVCR2, FABP1, MAVS | HCRTR1 4289/4885HCRTR2 4253/4885CASP3 4062/4885 |
| US-20190255067-A1 | HEPATITIS B CORE PROTEIN MODULATORS | HAVCR2, FABP1, MAVS | HCRTR1 4289/4885HCRTR2 4253/4885CASP3 4062/4885 |
| US-20220023311-A1 | HEPATITIS B CORE PROTEIN MODULATORS | HAVCR2, FABP1, MAVS | HCRTR1 4289/4885HCRTR2 4253/4885CASP3 4062/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.